drugset / Trial / NCT03730337

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

NCT03730337

Phase 1 Completed 24 enrolled Ono Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the tolerability and safety of ONO-7475 monotherapy and combinations with ONO-4538 in patients with advanced or metastatic solid tumors

Timeline

Start
2018-10-17
Primary completion
2021-06-28
Completion
2022-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody
Subject Tamnorzatinib Small molecule

Indications

No indication recorded.